Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an announcement.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has scheduled a board meeting for 28 April 2026 to review and approve the group’s first-quarter results for the period ended 31 March 2026. The company plans to publish these quarterly figures after board approval, signaling the upcoming disclosure of its early 2026 financial and operational performance to investors and the market.
The announcement also confirms the current composition of Fosun Pharma’s board, including executive, non-executive, independent non-executive, and employee directors. This stable governance structure underpins the company’s oversight of financial reporting and may provide stakeholders with continuity and transparency as the firm prepares to release its latest results.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a diversified healthcare company based in the People’s Republic of China, operating in the pharmaceutical and medical industry. The group focuses on the research, development, manufacturing, and distribution of medicines and related healthcare products, serving domestic and international markets.
Average Trading Volume: 2,881,866
Technical Sentiment Signal: Hold
Current Market Cap: HK$75.44B
Learn more about 2196 stock on TipRanks’ Stock Analysis page.